Home › NDC Lookup › RxCUI directory › RxCUI 2725917

Imlunestrant 200 MG Oral Tablet — RxCUI 2725917

RxNorm drug concept · Semantic clinical drug
RxCUI 2725917 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2725917
Official nameImlunestrant 200 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asimlunestrant 200 MG (equivalent to imlunestrant tosylate 265.66 MG) Oral Tablet
FDA products mapped1
Package NDCs mapped3
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Imlunestrant 200 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Imlunestrant 200 MG Oral Tablet RxCUI 2725917

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Imlunestrant 2725912
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Inluriyo 2725918
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Imlunestrant Oral Tablet 2725916
    • Imlunestrant Oral Product 2725914
    • Imlunestrant Pill 2725915
    • Imlunestrant Oral Tablet [Inluriyo] 2725922
    • Inluriyo Oral Product 2725920
    • Inluriyo Pill 2725921
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Imlunestrant 200 MG SCDC · 2725913
  • Imlunestrant Oral Tablet SCDF · 2725916
  • Imlunestrant Oral Product SCDG · 2725914
  • Imlunestrant Pill SCDG · 2725915

Brand-Name Concepts

  • Imlunestrant 200 MG Oral Tablet [Inluriyo] SBD · 2725923
  • Imlunestrant 200 MG [Inluriyo] SBDC · 2725919
  • Imlunestrant Oral Tablet [Inluriyo] SBDF · 2725922
  • Inluriyo Oral Product SBDG · 2725920
  • Inluriyo Pill SBDG · 2725921
  • Inluriyo BN · 2725918

📦 FDA Products & Package NDCs

1 product · 3 package NDCs
3 package NDCs map to RxCUI 2725917 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00002-1717-28 28 TABLET, FILM COATED in 1 BOTTLE (0002-1717-28) Inluriyo Eli Lilly and Company 2025-10-16
00002-1717-56 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-56) Inluriyo Eli Lilly and Company 2025-10-15
00002-1717-61 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-61) Inluriyo Eli Lilly and Company 2025-11-13
Observed labelers: Eli Lilly and Company (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.